Product Name: AMPSubtide
Product Number: PE-01BGI95
Size: 200 µg      Price:40.00
1 mg      $US80.00
5 mg      187.00
Peptide Name: AMPSubtide

Product Use: For assaying the phosphotransferase activity of 5'-AMP-activated protein kinase catalytic subunit alpha-2 (UniProt ID P54646).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: KKLRRRSFRNLG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 1705.3 Da

Peptide Purity Percent after Synthesis and Purification: >90

Peptide Appearance: White powder

Peptide Form: Solid
Storage Conditions: -20°C

Peptide Recommended Enzyme: AMP

Scientific Background: AMPKa2 (PRKAA2) is a protein-serine/threonine kinase of the CAMK group and CAMKL family. It is the catalytic subunit of AMP-activated protein kinase (AMPK),which is an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. It also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton. Binding of AMP results in allosteric activation, inducing phosphorylation on T172 by STK11 in complex with STE20-related adapter-alpha (STRAD alpha) pseudo kinase and CAB39.It is also activated by phosphorylation by CAMKK2 triggered by a rise in intracellular calcium ions, without detectable changes in the AMP/ATP ratio. Defects in PRKAA2 are linked to Peutz-Jeghers Syndrome, which is a relatively rare autosomal dominant disease where benign polyps develop on the GI tract.